AKT1 and glioblastoma: Genomic alterations resulting in EGFRvIII expression have been reported in glioblastoma, promoting downstream MAPK and PI3K/Akt signaling, and display responsiveness to epidermal growth factor receptor (EGFR) inhibition with gefitinib or lapatinib (14, 15).